The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling

Phase 2

Completed

• Conditions: Hypertension; Hypertrophy, Left Ventricular

• Registration Number: NCT00045994
• Lead Sponsor: Synvista Therapeutics, Inc

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal study in patients with left ventricular hypertrophy. Eligible patients will be randomized to double-blind treatment once daily for 6 months with oral ALT-711 (210 mg) or placebo.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-08
• Primary Completion: 2002-01
• Study First Submitted: 2002-09-17
• Study First Submitted QC: 2002-09-18
• Study First Posted: 2002-09-19
• Study Completion: 2003-06
• Status Verified: 2007-08
• Last Update Submitted: 2009-07-28
• Last Update Posted: 2009-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL